Patients were not rechallenged with the drug, but these reactions appear to be true side effects of benoxaprofen.
Introduction
Benoxaprofen (Opren, Dista) is a non-steroidal anti-inflammatory agent derived from propionic acid that has been on general release for over a year, during which time it has produced several unusual dermatological side effects. To alert practitioners of their unusual nature we record here the side effects seen in patients referred to our two departments, which serve a population of about 700 000.
Studies and results

PHOTOSENSITIVITY
Initial trials of benoxaprofen1 reported a 10%, incidence of photosensitivity rashes. Since many patients complained of burning, itching, or redness when in sunlight while taking the drug we investigated this in six consecutive patients with rheumatic disorders who were to receive treatment with benoxaprofen. These studies were carried out using an irradiation monochromator before and at least one week after benoxaprofen 600 mg was taken at night. Each patient lay prone, and a liquid-filled light guide conducted the radiation from the exit slit of the monochromator to the patient's back, an anatomical site that exhibits high sensitivity and uniformity to ultraviolet radiation. Patients were exposed to a range of doses of ultraviolet radiation in four different spectral regions, and the irradiation sites were examined during and immediately after exposure and also 24 hours later.
The patients gave normal responses to irradiation before treatment with benoxaprofen, but during treatment phototoxicity was found in all patients and was dominated by a transient reddening of the skin accompanied by a sensation of severe burning and itching and sometimes formation of weals. Wavelengths between 310 and 330 nm were the most effective in producing this response, and adverse immediate photoreactions occurred from exposure to ultraviolet radiation in this waveband at a small dose of around 1 J/cm2. Photosensitivityappeared to be confined to wavelengths less than 340 nm, since irradiation with a dose of 40 J/cm2 in the waveband 340 to 400 nm produced only immediate erythema localised to the irradiation site. This was in contrast to irradiation at wavelengths less than 340 nm, when in all cases immediate erythema was accompanied by a flare 2-3 cm in diameter around the irradiation site. Delayed photoresponses were not appreciably less than those observed in unsensitised skin.
Estimates of the terrestrial ultraviolet environment in the United Kingdom coupled with the action spectrum for benoxaprofen photosensitisation suggest that adverse immediate photoreactions may occur in midsummer after sunbathing for about 30 minutes at midday or after walking around outdoors for a few hours in the late morning and early afternoon. Calculations for other times of the year led to the conclusion that sunbathing should be avoided altogether and outdoor activities might have to be limited from about April to September. Indoor activities (apart from exposure to artificial sources of ultraviolet radiation) should not give rise to adverse photoresponses.
These phototests were carried out on unpigmented skin of the back; patients could expect some photoprotection from melanin if suntanned before starting treatment with benoxaprofen.
OTHER CUTANEOUS SIDE EFFECTS
We report below other cutaneous side effects seen in patients referred to our department. Routine haematological examination in these cases disclosed no abnormalities except those specified and included the following investigations: erythrocyte sedimentation rate, haemoglobin concentration, white cell count and differential, liver function tests, antinuclear factors, coagulation screen, and urine analysis.
Erythema multiforme and Stevens-Johnson syndrome-We previously reported one case of the Stevens-Johnson syndrome' and have now seen two further cases, as well as three cases-of erythema multiforme in which the cheeks were not affected. These patients had all been given benoxaprofen as sole treatment for arthritis (rheumatoid in two cases, osteoarthritis in four) and had been taking the drug for an average of six and a half weeks before symptoms developed. All lesions resolved within a month after treatment was stopped, although desquamation of palms continued in one case -for two months. Erythema multiforme and the Stevens-Johnson syndrome are potentially lethal conditions, and rechallenge with benoxaprofen would be unethical and was not carried out.
Milia-Eleven patients with milia of the face, all women aged 55-72 years (average 61 years), were referred to us. Lesions had developed gradually in all cases over an average of three and a half months of treatment with benoxaprofen. All patients had been taking benoxaprofen 600 mg daily as sole treatment for arthritic conditions. Nine patients had previously taken propionic-acid type non-steroidal antiinflammatory agents without this effect. Benoxaprofen was the first drug to be used in one case. The number of milia varied from one to nine. In one case the lesions resolved five months after treatment was stopped. In the 10 other cases the lesions appeared to be resolving slowly. The dermatological department sees about 11 000 new patients a year; in 1981 two patients presented with idiopathic milia. Milia of the face are not a recognised complication of osteoarthritis or rheumatoid arthritis. The patients refused to accept rechallenge with benoxaprofen.
Onycholysis-Onycholysis appears as a pale area where the nail is normally pink. Onycholysis due to benoxaprofen has been reported previously,' and we have now seen 19 cases. All patients had been taking benoxaprofen 600 mg daily for arthritic conditions for a mean of three months before noticing nail changes. Finger nails were affected in all cases, and in two cases a big toe nail was also affected. All patients were women aged 56-73 years (average 62 years). Two of the patients also had milia (see above). One patient presenting with erythema multiforme also had onycholysis. In three cases the condition resolved three months after treatment with benoxaprofen was stopped. We believe that this onycholysis may be due to a dose-related increase in the rate of growth of nail; since toe nails were affected it is probably not a light-induced reaction as is seen with treatment with tetracycline and psoralen-ultraviolet A radiation.
Pancytopenia and toxic epidermal necrolysis-We have been informed of one case3 in which this occurred during treatment with benoxaprofen but resolved after withdrawal of the drug.
Resolution of nodular prurigo-Histologically proved nodular prurigo in a 63-year-old woman who had been under our care for four years improved suddenly and considerably when she was given benoxaprofen 600 mg daily for arthritis. Nodular prurigo is a rare skin condition that does not resolve spontaneously and is unresponsive to treatment. Our patient had previously used topical and intralesional steroids and taken oral thalidomide without improvement.
Discussion
In our area we report all adverse effects of drugs to the regional clinical pharmacology unit, which passes them on to the Committee for the Safety of Medicines. The February issue of the Drug Newsletter4 issued by the regional clinical pharmacology unit noted that 212 reports of adverse drug reactions had been received since the regional reporting scheme started in June 1981, of which 310% were related to non-steroidal anti-inflammatory drugs; of these, benoxaprofen accounted for 40%, the most frequent reactions being rashes, photosensitivity, and onycholysis. Because. of these reports, and because we have noted over 10 cases of onycholysis and milia (which we rarely see in our department), we believe that these are true side effects and should be reported without waiting for the resolution of the eruptions. It would clearly be unethical to rechallenge patients with the Stevens-Johnson syndrome or erythema multiforme, which are potentially lethal conditions, and patients with onycholysis or milia are hardly likely to be willing to be rechallenged with the drug over a further two to three months in order to prove the causal link.
Phototoxicity due to benoxaprofen is a predictable side effect related to the dose of the drug and ultraviolet A radiation. MEDICINES COLD IN THE FIRST DEGREE-Those medicines which are least cold of all, obtain the first degree of coldness; and I beseech you take notice of this, that seeing our bodies are nourished by heat, and we live by heat, therefore no cold medicines are friendly to the body, but what good they do our bodies, they do it by removing an unnatural heat, or the body heated above it natural temper. The giving then of cold medicines to a man in his natural temper, the season of the year also being but moderately hot, extinguishes natural heat in the body of man.
Yet have these a necessary use in them too, though not so frequent as hot medicines have; and that may be the reason why an all wise God hath furnished us with far more hot herbs and plants, &c than cold. Their use is first, in nourishment, that so the heat of food may be qualified, and made for a weak stomach to digest. Secondly, To restrain and assuage the heat of the bowels, and to cool the blood in fevers. Therefore if the distemper of heat be but gentle, medicines cold in the first degree will suffice; also children, and such people whose stomachs are weak, are easily hurt by cold medicines.
